Figure 6
From: Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain
(A) PMM-172 suppressed constitutive pSTAT3 (Tyr705) in a dose-dependent manner. (B) PMM-172 suppressed constitutive pSTAT3 (Tyr705) in a time-dependent manner. (C) MDA-MB-231 cells were treated with IL-6 (20 ng/mL) or vehicle for 30 min, with or without pretreatment with PMM-172 (2 μM) for 24 h. PMM-172 inhibited IL-6 induced phosphorylation of STAT3. (D) Stattic suppressed constitutive pSTAT3 (Tyr705) in a dose-dependent manner. (E) Stattic suppressed constitutive pSTAT3 (Tyr705) in a time-dependent manner. (F) Tyrosine phosphorylation of two STAT family proteins STAT1 and STAT5 were detected with specific antibodies. PMM-172 inhibited neither the phosphorylation nor expression of STAT1 and STAT5. Data were shown as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01. Cropped blots/gels were used in the figure and the gels had been run under the same experimental conditions; the full-length blots/gels are presented in Supplementary Figure S2.
